In the published article, there was an error in Figure 5 as published. In Figure 5, the structure and name of the compound are incorrect. The corrected Figure 5 appears below.
FIGURE 5.
Structure-activity relationship of BAY1214784.
In the published article, the reference for Donnez et al., 1994 was incorrectly written as “Donnez, J., Nisolle, M., Clerckx, F., Casanas-Roux, F., Saussoy, P., and Gillerot, S. (1994). Advanced endoscopic techniques used in dysfunctional bleeding, fibroids and endometriosis, and the role of gonadotrophin-releasing hormone agonist treatment. Br J Obstet Gynaecol 101 Suppl 10, 2-9. doi: 10.1111/j.1471-0528.1994.tb13677.x.” It should be deleted.
In the published article, the reference for Carr et al., 2014 was incorrectly written as “Carr, B., Dmowski, W.P., O'Brien, C., Jiang, P., Burke, J., Jimenez, R., et al. (2014). Elagolix, an oral GnRH antagonist, versus subcutaneous depot medroxyprogesterone acetate for the treatment of endometriosis: effects on bone mineral density. Reprod Sci 21(11), 1341-1351. doi: 10.1177/1933719114549848.” It should be deleted.
In the published article, the reference for Donnez et al., 2020 was incorrectly written as “Donnez, J., Taylor, H.S., Taylor, R.N., Akin, M.D., Tatarchuk, T.F., Wilk, K., et al. (2020). Treatment of endometriosis-associated pain with linzagolix, an oral gonadotropin-releasing hormone-antagonist: a randomized clinical trial. Fertil Steril 114(1), 44-55. doi: 10.1016/j.fertnstert.2020.02.114.” It should be deleted.
A correction has been made to the Heading of 3.3.3. This heading previously stated:
“3.3.3 Linzagolix”
The corrected sentence appears below:
“3.3.3 BAY1214784”
A correction has been made to 3.3.3, paragraph 1. This sentence previously stated:
“Linzagolix (Figure 5) is an oral effective and highly selective hGnRH-A.”
The corrected sentence appears below:
“BAY1214784 (Figure 5) is an oral effective and highly selective hGnRH-A.”
A correction has been made to 3.3.3, paragraph 2. This sentence previously stated:
The pharmacokinetics studies further demonstrated BAY1214784 exhibits excellent features in vivo including an appropriate half-life of 15–18 h, high oral bioavailability, small amount of distribution, zero food effect, and no interaction with transporters or CYP3A4 enzymes (Donnez et al., 1994; Carr et al., 2014). Donnez et al. (Donnez et al., 2020) investigated the effect of BAY1214784 on treating endometriosis-related pain (EAP). The results showed that compared with placebo, BAY1214784 significantly alleviated the endometriosis-associated pain in the patients.
The sentences below need to be deleted. After the above sentences are deleted, the last sentence of paragraph 2 is merged into the first paragraph.
The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.